Mankind Pharma, 543904, MANKIND Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

1,08,915.11
55.50
1

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

1,07,913.17
N/A
11.02

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

-
-
9.92

EBITDA CAGR (%)

10 Years
5 Years
3 Years

-
-
4.97

PAT CAGR (%)

10 Years
5 Years
3 Years

-
-
10.09

P:E (Median)

8 Years
5 Years
3 Years

P:BV (Average)

8 Years
5 Years
3 Years

EV:EBITDA (Average)

8 Years
5 Years
3 Years

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Jun 24 Jun 23 Var% Mar 24 Mar 23 Var% Dec 23 Dec 22 Var% Sep 23 Sep 22 Var%
Net Sales 2,403.26 2,092.28 14.86% 2,152.69 1,872.12 14.99% 2,358.57 1,936.23 21.81% 2,453.35 2,257.55 8.67%
Expenses 1,831.06 1,594.32 14.85% 1,605.35 1,490.96 7.67% 1,755.46 1,562.74 12.33% 1,818.15 1,735.21 4.78%
EBITDA 572.20 497.96 14.91% 547.33 381.16 43.60% 603.11 373.50 61.48% 635.19 522.34 21.60%
EBIDTM 23.81% 23.80% 25.43% 20.36% 25.57% 19.29% 25.89% 23.14%
Other Income 94.83 57.44 65.09% 83.85 42.45 97.53% 67.23 32.40 107.50% 58.12 69.15 -15.95%
Interest 6.26 1.97 217.77% 4.03 0.89 352.81% 4.26 9.24 -53.90% 4.31 8.19 -47.37%
Depreciation 83.40 68.51 21.73% 82.29 67.30 22.27% 89.73 71.02 26.34% 77.04 66.04 16.66%
PBT 577.37 484.92 19.07% 544.86 355.43 53.30% 576.35 325.64 76.99% 611.96 517.25 18.31%
Tax 93.12 105.14 -11.43% 90.69 74.45 21.81% 89.28 76.76 16.31% 139.08 97.02 43.35%
PAT 484.25 379.78 27.51% 454.17 280.99 61.63% 487.07 248.87 95.71% 472.89 420.23 12.53%
PATM 20.15% 18.15% 21.10% 15.01% 20.65% 12.85% 19.28% 18.61%
EPS 12.09 9.48 27.53% 11.34 7.01 61.77% 12.16 6.21 95.81% 11.80 10.49 12.49%

Description Jun 24 Jun 23 Var% Mar 24 Mar 23 Var% Dec 23 Dec 22 Var% Sep 23 Sep 22 Var%
Net Sales 2,893.42 2,578.62 12.21% 2,441.10 2,052.67 18.92% 2,606.96 2,090.93 24.68% 2,708.10 2,425.84 11.64%
Expenses 2,211.66 1,923.81 14.96% 1,850.00 1,635.99 13.08% 2,000.45 1,653.89 20.95% 2,025.45 1,835.13 10.37%
EBITDA 681.76 654.81 4.12% 591.10 416.68 41.86% 606.50 437.04 38.77% 682.64 590.71 15.56%
EBIDTM 23.56% 25.39% 24.21% 20.30% 23.26% 20.90% 25.21% 24.35%
Other Income 100.60 58.62 71.61% 92.13 47.51 93.92% 70.13 37.14 88.83% 59.98 27.37 119.15%
Interest 10.91 6.34 72.08% 9.38 5.15 82.14% 9.18 12.77 -28.11% 8.62 10.31 -16.39%
Depreciation 107.74 87.35 23.34% 104.69 84.52 23.86% 109.73 84.79 29.41% 96.48 78.59 22.76%
PBT 663.71 619.74 7.09% 569.16 374.51 51.97% 557.73 376.63 48.08% 637.51 529.18 20.47%
Tax 124.55 130.28 -4.40% 94.98 83.59 13.63% 102.52 83.27 23.12% 129.81 110.39 17.59%
PAT 539.16 489.46 10.15% 474.18 290.93 62.99% 455.21 293.36 55.17% 507.70 418.80 21.23%
PATM 18.63% 18.98% 19.42% 14.17% 17.46% 14.03% 18.75% 17.26%
EPS 13.39 12.15 10.21% 11.76 7.13 64.94% 11.33 7.09 59.80% 12.51 10.48 19.37%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated

Description TTM Mar 24 Mar 23 Mar 22 Mar 21 Mar 14 Mar 13 Mar 12 Mar 11 Mar 10 Mar 09
Net Sales 9,367.87 9,264.81 8,127.15 7,486.22 5,523.18 2,288.59 1,971.77 1,650.57 1,406.88 1,085.77 840.27 Net Sales Growth 14.83% 14.00% 8.56% 35.54% 141.34% 16.07% 19.46% 17.32% 29.57% 29.22% Cost Of Goods Sold 2,805.50 2,908.30 2,844.76 2,521.44 1,782.17 974.33 868.10 758.68 -109.37 495.66 400.20 Gross Profit 6,562.37 6,356.51 5,282.39 4,964.78 3,741.02 1,314.26 1,103.66 891.90 1,516.25 590.11 440.07 GP Margin 70.05% 68.61% 65.00% 66.32% 67.73% 57.43% 55.97% 54.04% 107.77% 54.35% 52.37% Total Expenditure 7,010.02 6,939.19 6,429.29 5,647.73 4,151.05 1,818.41 1,580.87 1,393.29 1,134.38 850.03 667.63 Power & Fuel Cost - 70.43 62.00 60.36 47.16 6.76 4.45 2.99 0.00 2.10 1.53 % Of Sales - 0.76% 0.76% 0.81% 0.85% 0.30% 0.23% 0.18% 0% 0.19% 0.18% Employee Cost - 1,982.10 1,701.38 1,462.76 1,167.42 354.31 299.05 237.02 0.00 139.94 103.21 % Of Sales - 21.39% 20.93% 19.54% 21.14% 15.48% 15.17% 14.36% 0% 12.89% 12.28% Manufacturing Exp. - 159.11 129.91 165.08 131.09 11.79 10.10 2.38 0.00 4.69 4.14 % Of Sales - 1.72% 1.60% 2.21% 2.37% 0.52% 0.51% 0.14% 0% 0.43% 0.49% General & Admin Exp. - 877.22 914.90 620.52 367.12 173.51 146.50 108.14 1,243.75 65.75 42.79 % Of Sales - 9.47% 11.26% 8.29% 6.65% 7.58% 7.43% 6.55% 88.40% 6.06% 5.09% Selling & Distn. Exp. - 806.36 607.88 686.50 482.85 168.11 237.69 272.55 0.00 139.71 111.92 % Of Sales - 8.70% 7.48% 9.17% 8.74% 7.35% 12.05% 16.51% 0% 12.87% 13.32% Miscellaneous Exp. - 135.67 168.47 131.08 173.25 129.61 14.98 11.52 0.00 2.18 111.92 % Of Sales - 1.46% 2.07% 1.75% 3.14% 5.66% 0.76% 0.70% 0% 0.20% 0.46% EBITDA 2,357.83 2,325.62 1,697.86 1,838.49 1,372.13 470.18 390.90 257.28 272.50 235.74 172.64 EBITDA Margin 25.17% 25.10% 20.89% 24.56% 24.84% 20.54% 19.82% 15.59% 19.37% 21.71% 20.55% Other Income 304.03 266.64 162.78 203.81 154.50 43.61 30.91 33.96 23.85 19.68 19.17 Interest 18.86 15.08 28.23 47.54 8.23 1.66 1.57 1.55 0.00 1.52 2.38 Depreciation 332.46 317.61 269.58 123.33 78.19 26.55 23.78 11.47 7.76 4.44 4.20 PBT 2,310.54 2,259.57 1,562.84 1,871.44 1,440.21 485.58 396.45 278.23 288.59 249.46 185.24 Tax 412.17 436.16 314.58 482.01 355.83 141.38 105.88 64.53 81.70 77.44 64.69 Tax Rate 17.84% 19.30% 20.13% 25.76% 24.71% 29.12% 26.71% 23.19% 28.31% 31.04% 34.92% PAT 1,898.38 1,823.41 1,248.26 1,389.42 1,084.37 344.20 290.57 213.69 206.89 172.02 120.55 PAT before Minority Interest 1,898.38 1,823.41 1,248.26 1,389.42 1,084.37 344.20 290.57 213.69 206.89 172.02 120.55 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 20.26% 19.68% 15.36% 18.56% 19.63% 15.04% 14.74% 12.95% 14.71% 15.84% 14.35% PAT Growth 42.75% 46.08% -10.16% 28.13% 215.04% 18.46% 35.98% 3.29% 20.27% 42.70% EPS 47.39 45.52 31.16 34.68 27.07 8.59 7.25 5.33 5.16 4.29 3.01

Description TTM Mar 24 Mar 23 Mar 22 Mar 21
Net Sales 10,649.58 10,334.77 8,749.43 7,781.56 6,214.43 Net Sales Growth 16.41% 18.12% 12.44% 25.22% Cost Of Goods Sold 3,202.27 3,209.70 2,913.64 2,421.73 1,780.60 Gross Profit 7,447.31 7,125.08 5,835.79 5,359.83 4,433.82 GP Margin 69.93% 68.94% 66.70% 68.88% 71.35% Total Expenditure 8,087.56 7,798.19 6,847.50 5,791.01 4,565.32 Power & Fuel Cost - 129.30 108.96 103.13 82.53 % Of Sales - 1.25% 1.25% 1.33% 1.33% Employee Cost - 2,274.73 1,918.47 1,620.59 1,415.78 % Of Sales - 22.01% 21.93% 20.83% 22.78% Manufacturing Exp. - 174.04 150.57 189.81 140.14 % Of Sales - 1.68% 1.72% 2.44% 2.26% General & Admin Exp. - 982.88 1,000.80 626.47 451.75 % Of Sales - 9.51% 11.44% 8.05% 7.27% Selling & Distn. Exp. - 928.75 638.11 708.17 587.73 % Of Sales - 8.99% 7.29% 9.10% 9.46% Miscellaneous Exp. - 98.80 116.96 121.10 106.78 % Of Sales - 0.96% 1.34% 1.56% 1.72% EBITDA 2,562.00 2,536.58 1,901.93 1,990.55 1,649.11 EBITDA Margin 24.06% 24.54% 21.74% 25.58% 26.54% Other Income 322.84 280.86 128.57 196.03 170.95 Interest 38.09 35.05 45.76 59.80 21.16 Depreciation 418.64 398.25 325.92 166.62 118.97 PBT 2,428.11 2,384.14 1,658.81 1,960.15 1,679.93 Tax 451.86 457.59 361.56 521.64 398.58 Tax Rate 18.61% 19.19% 21.80% 26.61% 23.73% PAT 1,976.25 1,912.89 1,281.86 1,433.48 1,265.42 PAT before Minority Interest 1,948.12 1,941.77 1,309.68 1,452.96 1,293.03 Minority Interest -28.13 -28.88 -27.82 -19.48 -27.61 PAT Margin 18.56% 18.51% 14.65% 18.42% 20.36% PAT Growth 32.41% 49.23% -10.58% 13.28% EPS 49.33 47.75 32.00 35.78 31.59

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 14 Mar 13 Mar 12 Mar 11 Mar 10 Mar 09
Shareholder's Funds 9,623.81 7,783.91 6,540.45 4,734.27 1,555.50 1,211.29 920.72 706.73 499.84 333.59 Share Capital 40.06 40.06 40.06 40.06 20.03 20.03 20.03 20.03 14.84 14.84 Total Reserves 9,560.50 7,743.79 6,500.39 4,694.21 1,535.47 1,191.26 900.69 686.70 485.00 318.76 Non-Current Liabilities 200.54 168.12 126.98 54.11 31.36 29.46 28.49 25.41 5.78 9.09 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.71 7.27 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 111.79 88.87 73.79 56.39 4.84 2.08 1.98 4.64 0.00 0.00 Current Liabilities 1,593.36 1,419.09 2,271.27 1,078.91 593.98 540.34 474.53 364.76 233.24 171.76 Trade Payables 849.52 801.96 921.29 594.08 175.79 149.57 203.89 157.88 99.49 68.31 Other Current Liabilities 328.65 279.51 399.57 196.75 108.74 65.19 51.51 46.95 54.77 38.85 Short Term Borrowings 0.00 0.00 683.66 95.00 0.03 0.00 0.00 0.80 0.00 0.00 Short Term Provisions 415.20 337.61 266.74 193.08 309.42 325.58 219.13 159.13 78.99 64.60 Total Liabilities 11,417.71 9,371.12 8,938.70 5,867.29 2,180.84 1,781.09 1,423.74 1,096.90 738.86 514.44 Net Block 3,399.07 3,136.89 2,921.30 981.95 202.69 202.56 177.72 74.60 84.62 58.26 Gross Block 4,336.83 3,770.10 3,286.82 1,221.61 286.14 259.54 210.98 96.68 99.12 68.46 Accumulated Depreciation 937.76 633.21 365.51 239.65 83.45 56.98 33.26 22.08 14.50 10.20 Non Current Assets 5,927.30 5,854.21 5,122.99 2,777.31 568.46 529.02 383.14 195.13 248.34 148.55 Capital Work in Progress 187.58 494.78 386.57 165.57 21.37 6.44 0.43 18.11 7.30 0.21 Non Current Investment 2,190.62 2,040.76 1,657.08 1,500.86 109.51 87.66 27.01 12.47 156.42 90.08 Long Term Loans & Adv. 137.64 148.86 146.30 115.59 218.84 167.59 110.92 39.79 0.00 0.00 Other Non Current Assets 7.11 27.58 6.37 7.88 16.05 64.77 67.05 50.16 0.00 0.00 Current Assets 5,487.71 3,513.72 3,813.01 3,089.98 1,612.38 1,252.07 1,040.60 901.76 490.52 365.81 Current Investments 2,239.51 1,061.47 868.79 896.03 689.05 350.46 149.15 247.22 0.00 0.00 Inventories 1,075.59 1,032.22 1,266.69 826.91 337.19 312.67 361.73 271.93 153.55 116.63 Sundry Debtors 749.47 492.64 470.59 369.17 131.59 112.41 141.39 113.40 93.30 70.77 Cash & Bank 761.01 155.15 138.85 476.95 99.96 104.51 89.15 83.41 99.55 59.61 Other Current Assets 662.13 59.05 166.44 106.01 354.59 372.02 299.18 185.81 144.12 118.81 Short Term Loans & Adv. 572.15 713.20 901.65 414.91 351.81 372.02 299.18 184.89 144.12 118.81 Net Current Assets 3,894.35 2,094.63 1,541.74 2,011.07 1,018.40 711.73 566.07 537.00 257.28 194.06 Total Assets 11,415.01 9,367.93 8,936.00 5,867.29 2,180.84 1,781.09 1,423.74 1,096.89 738.86 514.43

Description Mar 24 Mar 23 Mar 22 Mar 21
Shareholder's Funds 9,363.09 7,435.22 6,155.23 4,722.00 Share Capital 40.06 40.06 40.06 40.06 Total Reserves 9,299.78 7,395.10 6,115.17 4,681.94 Non-Current Liabilities 187.34 199.24 168.68 107.33 Secured Loans 24.87 23.15 48.94 57.42 Unsecured Loans 0.00 0.00 0.25 0.25 Long Term Provisions 123.12 97.89 80.00 72.24 Current Liabilities 2,119.73 1,863.14 2,623.46 1,353.40 Trade Payables 1,102.99 1,008.18 1,076.40 666.97 Other Current Liabilities 429.58 386.05 472.89 282.77 Short Term Borrowings 151.47 115.02 794.59 158.35 Short Term Provisions 435.69 353.89 279.59 245.30 Total Liabilities 11,882.86 9,685.67 9,108.45 6,323.62 Net Block 4,539.96 4,245.28 3,582.77 1,658.94 Gross Block 5,909.75 5,233.03 4,246.54 2,160.04 Accumulated Depreciation 1,369.79 987.75 663.78 501.10 Non Current Assets 5,314.63 5,357.80 4,701.63 2,416.98 Capital Work in Progress 281.79 550.15 701.47 371.95 Non Current Investment 309.81 270.95 235.01 205.80 Long Term Loans & Adv. 163.97 187.54 163.88 158.07 Other Non Current Assets 13.79 98.51 13.09 16.72 Current Assets 6,565.52 4,324.56 4,403.84 3,906.64 Current Investments 2,258.11 1,075.47 874.46 1,306.17 Inventories 1,553.46 1,498.46 1,760.24 1,183.54 Sundry Debtors 848.28 576.42 388.17 330.61 Cash & Bank 1,197.97 453.20 405.94 700.74 Other Current Assets 707.70 64.29 170.74 109.78 Short Term Loans & Adv. 603.60 656.71 804.29 275.79 Net Current Assets 4,445.79 2,461.42 1,780.37 2,553.24 Total Assets 11,880.15 9,682.36 9,105.47 6,323.62

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 14 Mar 13 Mar 12 Mar 11 Mar 10 Mar 09
Cash From Operating Activity 1,982.97 1,798.99 821.44 983.38 355.00 302.53 -12.85 76.28 134.50 72.38 PBT 2,259.57 1,562.84 1,871.44 1,440.21 485.58 396.45 278.23 288.59 249.46 185.24 Adjustment 161.91 227.00 -4.16 96.74 -15.62 -5.64 -21.00 -14.54 -13.65 -12.29 Changes in Working Capital -40.95 294.21 -585.61 -156.19 16.75 7.20 -185.29 -109.07 -16.87 -36.94 Cash after chg. in Working capital 2,380.53 2,084.05 1,281.67 1,380.76 486.71 398.02 71.94 164.97 218.94 136.01 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -397.55 -285.06 -460.22 -397.38 -131.71 -95.49 -84.79 -88.69 -84.44 -63.63 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -1,919.12 -1,040.61 -1,360.27 -1,127.16 -358.15 -285.77 20.74 -87.97 -84.29 -57.53 Net Fixed Assets -259.53 -591.49 -2,286.21 -1,079.67 -41.53 -54.57 -96.62 -8.37 -37.75 -59.17 Net Investments -1,327.90 -576.36 -128.98 -1,598.33 -360.44 -261.96 83.53 -103.27 -66.34 -85.29 Others -331.69 127.24 1,054.92 1,550.84 43.82 30.76 33.83 23.67 19.80 86.93 Cash from Financing Activity -8.68 -710.41 578.63 88.87 -1.41 -1.40 -2.15 -4.46 -10.27 -12.71 Net Cash Inflow / Outflow 55.17 47.96 39.81 -54.91 -4.55 15.36 5.74 -16.14 39.94 2.14 Opening Cash & Equivalents 134.13 86.17 46.36 77.50 104.51 89.15 83.41 99.55 59.61 57.47 Closing Cash & Equivalent 189.20 134.13 86.17 22.58 99.96 104.51 89.15 83.41 99.55 59.61

Description Mar 24 Mar 23 Mar 22 Mar 21
Cash From Operating Activity 2,152.45 1,813.30 919.78 1,137.24 PBT 2,399.36 1,671.24 1,974.60 1,691.61 Adjustment 212.20 298.43 30.81 -5.66 Changes in Working Capital 20.42 166.73 -586.12 -94.63 Cash after chg. in Working capital 2,631.98 2,136.40 1,419.29 1,591.32 Interest Paid 0.00 0.00 0.00 0.00 Tax Paid -479.53 -323.10 -499.51 -454.07 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 Cash From Investing Activity -2,081.69 -1,054.13 -1,369.14 -1,222.21 Net Fixed Assets -259.53 -591.49 -2,286.21 Net Investments -1,327.90 -576.36 -128.98 Others -494.26 113.72 1,046.05 Cash from Financing Activity 5.27 -739.73 604.62 -7.81 Net Cash Inflow / Outflow 76.02 19.44 155.26 -92.78 Opening Cash & Equivalents 304.82 283.06 127.33 219.73 Closing Cash & Equivalent 382.01 304.82 283.06 127.33

Financial Ratios

Standalone /

Consolidated

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 14 Mar 13 Mar 12 Mar 11 Mar 10 Mar 09
Book Value (Rs.) 239.66 194.31 163.27 118.18 776.61 604.76 459.68 352.84 336.89 224.80 ROA 17.54% 13.63% 18.77% 20.90% 17.38% 18.13% 16.96% 22.54% 27.45% 40.07% ROE 20.98% 17.43% 24.65% 25.86% 24.88% 27.26% 26.26% 34.29% 41.28% 66.91% ROCE 26.13% 21.20% 31.84% 34.16% 35.22% 37.34% 34.37% 47.66% 59.45% 99.58% Fixed Asset Turnover 2.37 2.40 3.45 4.73 8.39 8.38 10.73 14.37 12.96 21.61 Receivable days 23.55 20.75 19.69 26.03 19.46 23.49 28.17 26.81 27.58 19.61 Inventory Days 39.97 49.52 49.10 44.95 51.82 62.42 70.06 55.19 45.41 33.51 Payable days 103.63 110.55 109.68 110.73 37.38 44.99 47.49 0.00 37.71 27.75 Cash Conversion Cycle -40.11 -40.28 -40.89 -39.75 33.90 40.92 50.75 82.01 35.28 25.36 Total Debt/Equity 0.00 0.00 0.10 0.02 0.00 0.00 0.00 0.00 0.01 0.02 Interest Cover 150.83 56.36 40.37 175.93 294.17 253.23 180.56 0.00 165.50 78.96

Description Mar 24 Mar 23 Mar 22 Mar 21
Book Value (Rs.) 233.15 185.61 153.65 117.88 ROA 18.01% 13.94% 18.83% 22.79% ROE 23.15% 19.27% 26.72% 31.51% ROCE 28.38% 23.49% 33.96% 39.97% Fixed Asset Turnover 1.93 1.92 2.52 3.00 Receivable days 24.18 19.33 16.25 25.31 Inventory Days 51.80 65.31 66.57 61.16 Payable days 120.04 130.57 131.38 144.73 Cash Conversion Cycle -44.05 -45.92 -48.56 -58.26 Total Debt/Equity 0.02 0.02 0.14 0.05 Interest Cover 69.46 37.52 34.02 80.96

Top Investors:

sbi nifty midcap 150 index fund

government pension fund global

tata aia life insurance company limited a/c group

Annual Reports:

News Update:

Mankind Pharma completes transaction to acquire 100% stake in Bharat Serums and Vaccines
24th Oct 2024, 09:39 AM

BSV’s established domestic product portfolio offers huge scalability potential through strong registration velocity through niche filings across international markets
Read More
Mankind Pharma to transfer OTC business undertaking to MCPPL
4th Sep 2024, 09:29 AM

The completion of slump sale of OTC Business Undertaking to MCPPL is subject to pre-conditions, closing actions and other terms and conditions as specified in the BTA
Read More
Mankind Pharma’s Q1FY25 consolidated net profit surges by 10%
31st Jul 2024, 15:57 PM

Total consolidated income of the company increased by 13.53% at Rs 2,994.02 crore for Q1FY25
Read More
Mankind Pharma - Quarterly Results
31st Jul 2024, 14:47 PM

Read More

Mankind Pharma Ltd.

Pharmaceuticals & Drugs

BSE: 543904 | NSE: MANKIND

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores /

Results Balance Sheet

Standalone Figures in Rs. Crores /

Cash Flow

Standalone Figures in Rs. Crores /

Financial Ratios

Standalone /

Top Investors:

Annual Reports:

News Update:

Mankind Pharma Ltd.

Pharmaceuticals & Drugs

BSE: 543904 | NSE: MANKIND

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores /

Results Balance Sheet

Standalone Figures in Rs. Crores /

Cash Flow

Standalone Figures in Rs. Crores /

Financial Ratios

Standalone /

Top Investors:

Annual Reports:

News Update: